Corcept Therapeutics Incorporated Stock Market Value
| CORT Stock | USD 40.83 0.14 0.34% |
| Symbol | Corcept |
Is there potential for Pharmaceuticals market expansion? Will Corcept introduce new products? Factors like these will boost the valuation of Corcept Therapeutics. Projected growth potential of Corcept fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Corcept Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.61) | Earnings Share 0.87 | Revenue Per Share | Quarterly Revenue Growth 0.137 | Return On Assets |
Understanding Corcept Therapeutics requires distinguishing between market price and book value, where the latter reflects Corcept's accounting equity. The concept of intrinsic value - what Corcept Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Corcept Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Corcept Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Corcept Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Corcept Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Corcept Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Corcept Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Corcept Therapeutics.
| 11/14/2025 |
| 02/12/2026 |
If you would invest 0.00 in Corcept Therapeutics on November 14, 2025 and sell it all today you would earn a total of 0.00 from holding Corcept Therapeutics Incorporated or generate 0.0% return on investment in Corcept Therapeutics over 90 days. Corcept Therapeutics is related to or competes with Halozyme Therapeutics, Abivax SA, Rhythm Pharmaceuticals, Cytokinetics, Jazz Pharmaceuticals, Caris Life, and Axsome Therapeutics. Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, o... More
Corcept Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Corcept Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Corcept Therapeutics Incorporated upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 55.08 | |||
| Value At Risk | (8.51) | |||
| Potential Upside | 6.44 |
Corcept Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Corcept Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Corcept Therapeutics' standard deviation. In reality, there are many statistical measures that can use Corcept Therapeutics historical prices to predict the future Corcept Therapeutics' volatility.| Risk Adjusted Performance | (0.05) | |||
| Jensen Alpha | (0.76) | |||
| Total Risk Alpha | (1.39) | |||
| Treynor Ratio | (0.20) |
Corcept Therapeutics February 12, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | (0.19) | |||
| Mean Deviation | 3.54 | |||
| Coefficient Of Variation | (1,465) | |||
| Standard Deviation | 7.39 | |||
| Variance | 54.63 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.76) | |||
| Total Risk Alpha | (1.39) | |||
| Treynor Ratio | (0.20) | |||
| Maximum Drawdown | 55.08 | |||
| Value At Risk | (8.51) | |||
| Potential Upside | 6.44 | |||
| Skewness | (4.82) | |||
| Kurtosis | 32.5 |
Corcept Therapeutics Backtested Returns
Corcept Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0797, which signifies that the company had a -0.0797 % return per unit of risk over the last 3 months. Corcept Therapeutics Incorporated exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Corcept Therapeutics' Standard Deviation of 7.39, risk adjusted performance of (0.05), and Mean Deviation of 3.54 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 2.6, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Corcept Therapeutics will likely underperform. At this point, Corcept Therapeutics has a negative expected return of -0.61%. Please make sure to confirm Corcept Therapeutics' jensen alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Corcept Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.21 |
Weak reverse predictability
Corcept Therapeutics Incorporated has weak reverse predictability. Overlapping area represents the amount of predictability between Corcept Therapeutics time series from 14th of November 2025 to 29th of December 2025 and 29th of December 2025 to 12th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Corcept Therapeutics price movement. The serial correlation of -0.21 indicates that over 21.0% of current Corcept Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.21 | |
| Spearman Rank Test | 0.51 | |
| Residual Average | 0.0 | |
| Price Variance | 92.88 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.